2. Academic Validation
  3. Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6

Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6

  • Bioorg Med Chem Lett. 2015 Jun 1;25(11):2382-5. doi: 10.1016/j.bmcl.2015.04.016.
Maxim V Kozlov 1,  Alla A Kleymenova 2,  Lyudmila I Romanova 3,  Konstantin A Konduktorov 2,  Kamila A Kamarova 2,  Olga A Smirnova 2,  Vladimir S Prassolov 2,  Sergey N Kochetkov 2
Affiliations

Affiliations

  • 1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str. 32, 119991 Moscow, Russia. Electronic address: [email protected].
  • 2 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str. 32, 119991 Moscow, Russia.
  • 3 Chumakov Institute of Poliomyelitis, Russian Academy of Medical Sciences, 142782 Moscow Region, Russia.
PMID: 25937017 DOI: 10.1016/j.bmcl.2015.04.016
Abstract

Recently we reported benzohydroxamic acids (BHAs) as potent and selective inhibitors of hepatitis C virus (HCV) replicon propagation. In this work 12 pyridine hydroxamic acids (PHAs) were synthesized and tested in full-genome replicon assay. It was found that PHAs possessed very similar anti-HCV properties compared to BHAs. Both classes of hydroxamic acids caused hyperacetylation of α-tubulin pointing to inhibition of histone deacetylase 6 (HDAC6) as part of their Antiviral activity. The tested compounds did not inhibit the growth of poliovirus, displaying high selectivity against HCV.

Keywords

Benzohydroxamic acids; Hepatitis C virus; Histone deacetylase 6; Pyridine hydroxamic acids; α-Tubulin.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-W555601
    99.05%, HCV/HDAC6 Inhibitor